Enliven Therapeutics Inc.

19.93
1.05 (5.56%)
At close: Apr 02, 2025, 3:59 PM
19.56
-1.82%
After-hours: Apr 02, 2025, 04:35 PM EDT

Company Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene.

The company is based in Boulder, Colorado.

Enliven Therapeutics Inc.
Enliven Therapeutics Inc. logo
Country United States
IPO Date Mar 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 62
CEO Samuel S. Kintz M.B.A.

Contact Details

Address:
6200 Lookout Road
Boulder, Colorado
United States
Website https://www.enliventherapeutics.com

Stock Details

Ticker Symbol ELVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001672619
CUSIP Number 29337E102
ISIN Number US29337E1029
Employer ID 81-1523849
SIC Code 2834

Key Executives

Name Position
Samuel S. Kintz M.B.A. Co-Founder, Chief Executive Officer, Secretary & Director
Anish Patel Pharm.D. Co-Founder & Chief Operating Officer
Benjamin Hohl Chief Financial Officer & Head of Corporate Development
Dr. Galya D. Blachman Esq., Ph.D. Chief Legal Officer & Head of Business Development
Dr. Helen Louise Collins M.D. Chief Medical Officer
Dr. Joseph P. Lyssikatos Ph.D. Co-Founder & Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 31, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 21, 2025 4 Filing
Mar 19, 2025 4 Filing
Mar 13, 2025 S-8 Filing
Mar 13, 2025 10-K Annual Report
Mar 13, 2025 8-K Current Report
Mar 11, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 03, 2025 4 Filing